Jyong Biotech (NASDAQ:MENS) Shares Up 15.1% – Here’s Why

by · The Markets Daily

Jyong Biotech Ltd. (NASDAQ:MENS – Get Free Report) shares rose 15.1% on Monday . The stock traded as high as $31.32 and last traded at $31.32. Approximately 47,130 shares traded hands during trading, a decline of 83% from the average daily volume of 284,691 shares. The stock had previously closed at $27.20.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Jyong Biotech in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Jyong Biotech presently has an average rating of “Sell”.

Get Our Latest Stock Analysis on MENS

Jyong Biotech Price Performance

The company’s fifty day moving average price is $46.42.

Institutional Trading of Jyong Biotech

A hedge fund recently bought a new stake in Jyong Biotech stock. BNP Paribas Financial Markets bought a new stake in Jyong Biotech Ltd. (NASDAQ:MENS – Free Report) during the third quarter, according to its most recent filing with the SEC. The firm bought 1,698 shares of the company’s stock, valued at approximately $67,000.

Jyong Biotech Company Profile

(Get Free Report)

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.

Further Reading